

Noile-Immune Biotech Enters Collaboration with DAIICHI SANKYO COMPANY, LIMITED on Technology Assessment

Tokyo, Japan (October 25, 2021) - Noile-Immune Biotech Inc. (“Noile-Immune”) today announced that Noile-Immune and DAIICHI SANKYO COMPANY, LIMITED (“Daiichi Sankyo”) have entered into the agreement regarding PRIME (Proliferation inducing and migration enhancing) technology assessment.

PRIME technology has a capability of not only enhancing the functions of gene-modified immune cells such as CAR-T cells, but also improving the ability of patient's own immune systems to treat cancer¹⁾. Noile-Immune has the exclusive right to implement PRIME technology.

Under this agreement, Daiichi Sankyo will evaluate Noile-Immune’s PRIME technology with collaborative works with Noile-Immune, and Daiichi Sankyo will pay Noile-Immune the technology access fee. Further details of this agreement are not disclosed.

1) Adachi K et al. *Nat Biotechnol*, 2018;36(4):346-351.

